| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Daniel Schöttle, Wolfgang Janetzky, Daniel Luedecke, Elmar Beck, Christoph U Correll, Klaus Wiedeman. The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index. BMC psychiatry. vol 20. issue 1. 2020-12-21. PMID:32087718. |
in this non-interventional study, the functionality and well-being of patients with schizophrenia with aripiprazole once-monthly (aom) was evaluated under real-life conditions in a naturalistic population. |
2020-12-21 |
2023-08-13 |
Not clear |
| Hidenobu Suzuki, Hiroyuki Hibino, Atsuhiko Takaya, Yuichi Inou. The effect of aripiprazole once-monthly 300 mg in maintenance therapy for schizophrenia. Asian journal of psychiatry. vol 47. 2020-12-10. PMID:31655461. |
the effect of aripiprazole once-monthly 300 mg in maintenance therapy for schizophrenia. |
2020-12-10 |
2023-08-13 |
Not clear |
| Tinkara Pirc Marolt, Barbara Kramar, Klara Bulc Rozman, Dušan Šuput, Irina Milisa. Aripiprazole reduces liver cell division. PloS one. vol 15. issue 10. 2020-12-08. PMID:33104743. |
effects of aripiprazole on dopamine regulation are being tested as a treatment for patients with a dual diagnosis of schizophrenia and addictions, often cocaine dependence. |
2020-12-08 |
2023-08-13 |
Not clear |
| John Lauriello, Amy Claxton, Yangchun Du, Peter J Weide. Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study. The Journal of clinical psychiatry. vol 81. issue 5. 2020-11-23. PMID:32841554. |
beyond 52-week long-term safety: long-term outcomes of aripiprazole lauroxil for patients with schizophrenia continuing in an extension study. |
2020-11-23 |
2023-08-13 |
Not clear |
| John Lauriello, Amy Claxton, Yangchun Du, Peter J Weide. Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study. The Journal of clinical psychiatry. vol 81. issue 5. 2020-11-23. PMID:32841554. |
to describe the long-term safety, tolerability, and symptom trajectory with the long-acting injectable antipsychotic aripiprazole lauroxil (al) in patients with dsm-5-diagnosed schizophrenia followed for up to 180 weeks (3.5 years). |
2020-11-23 |
2023-08-13 |
Not clear |
| Jeaneun Park, Kwang-Hyun Cho, Hong Joon Lee, Jin-Sung Choi, Duck-Joo Rhi. Open channel block of Kv1.4 potassium channels by aripiprazole. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology. vol 24. issue 6. 2020-11-01. PMID:33093275. |
aripiprazole is a quinolinone derivative approved as an atypical antipsychotic drug for the treatment of schizophrenia and bipolar disorder. |
2020-11-01 |
2023-08-13 |
Not clear |
| Iara Carolina Barbosa Henrique, Tácio de Mendonça Lima, Daniela Oliveira de Melo, Patricia Melo Aguia. Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review. Journal of clinical pharmacy and therapeutics. vol 45. issue 1. 2020-10-07. PMID:31436857. |
economic evaluations on the use of aripiprazole for patients with schizophrenia: a systematic review. |
2020-10-07 |
2023-08-13 |
Not clear |
| Iara Carolina Barbosa Henrique, Tácio de Mendonça Lima, Daniela Oliveira de Melo, Patricia Melo Aguia. Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review. Journal of clinical pharmacy and therapeutics. vol 45. issue 1. 2020-10-07. PMID:31436857. |
however, there is a lack of information on the reporting quality of economic evaluations, cost drivers, as well as updated data focused on aripiprazole, an antipsychotic drug commonly prescribed in schizophrenia. |
2020-10-07 |
2023-08-13 |
Not clear |
| Iara Carolina Barbosa Henrique, Tácio de Mendonça Lima, Daniela Oliveira de Melo, Patricia Melo Aguia. Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review. Journal of clinical pharmacy and therapeutics. vol 45. issue 1. 2020-10-07. PMID:31436857. |
this study evaluates and summarizes the evidence of economic evaluations of the use of aripiprazole in schizophrenia. |
2020-10-07 |
2023-08-13 |
Not clear |
| Christophe Sapin, Ann Hartry, Siddhesh A Kamat, Maud Beillat, Ross A Baker, Anna Eram. Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis. Drugs in context. vol 5. 2020-10-01. PMID:27708677. |
pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a us analysis. |
2020-10-01 |
2023-08-13 |
Not clear |
| Christophe Sapin, Ann Hartry, Siddhesh A Kamat, Maud Beillat, Ross A Baker, Anna Eram. Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis. Drugs in context. vol 5. 2020-10-01. PMID:27708677. |
in quality of life with abilify maintena (qualify), a randomized head-to-head study of aripiprazole once-monthly 400 mg (aom 400) compared with paliperidone palmitate (pp; 78-234 mg/mo), aom 400 demonstrated greater improvement in health-related quality of life and functioning in patients with stable schizophrenia. |
2020-10-01 |
2023-08-13 |
Not clear |
| Timothy Peters-Strickland, Linda Pestreich, Ainslie Hatch, Shashank Rohatagi, Ross A Baker, John P Docherty, Lada Markovtsova, Praveen Raja, Peter J Weiden, David P Wallin. Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole. Neuropsychiatric disease and treatment. vol 12. 2020-10-01. PMID:27785036. |
usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole. |
2020-10-01 |
2023-08-13 |
Not clear |
| Timothy Peters-Strickland, Linda Pestreich, Ainslie Hatch, Shashank Rohatagi, Ross A Baker, John P Docherty, Lada Markovtsova, Praveen Raja, Peter J Weiden, David P Wallin. Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole. Neuropsychiatric disease and treatment. vol 12. 2020-10-01. PMID:27785036. |
this study evaluated usability of the dms in adults with schizophrenia rated by both patients and their health care providers (hcps) during 8-week treatment with prescribed doses of digital aripiprazole. |
2020-10-01 |
2023-08-13 |
Not clear |
| Britta Galling, Alexandra Roldán, Katsuhiko Hagi, Liz Rietschel, Frozan Walyzada, Wei Zheng, Xiao-Lan Cao, Yu-Tao Xiang, Mathias Zink, John M Kane, Jimmi Nielsen, Stefan Leucht, Christoph U Correl. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World psychiatry : official journal of the World Psychiatric Association (WPA). vol 16. issue 1. 2020-10-01. PMID:28127934. |
these data suggest that the common practice of antipsychotic augmentation in schizophrenia lacks double-blind/high-quality evidence for efficacy, except for negative symptom reduction with aripiprazole augmentation. |
2020-10-01 |
2023-08-13 |
Not clear |
| Phyllis M Salzman, Arash Raoufinia, Susan Legacy, Pedro Such, Anna Eram. Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole. Neuropsychiatric disease and treatment. vol 13. 2020-10-01. PMID:28461748. |
aripiprazole is an atypical antipsychotic used in the treatment of schizophrenia and is available in 2 chemically different (aripiprazole monohydrate and aripiprazole lauroxil [al]) and pharmaceutically different lai formulations (aripiprazole once-monthly 400 mg [aom 400] and al). |
2020-10-01 |
2023-08-13 |
Not clear |
| Hidenobu Suzuki, Hiroyuki Hibino, Yuichi Inoue, Hideo Matsumoto, Katsunaka Mikam. The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia. SAGE open medical case reports. vol 5. 2020-10-01. PMID:28596830. |
the effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia. |
2020-10-01 |
2023-08-13 |
Not clear |
| Corrigendum: Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis. Drugs in context. vol 6. 2020-10-01. PMID:28706556. |
corrigendum: pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a us analysis. |
2020-10-01 |
2023-08-13 |
Not clear |
| Eiji Kirin. Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics. Annals of general psychiatry. vol 16. 2020-10-01. PMID:29209406. |
serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics. |
2020-10-01 |
2023-08-13 |
Not clear |
| Yuki Omori, Takashi Kanbayashi, Yohei Sagawa, Aya Imanishi, Ko Tsutsui, Yuya Takahashi, Masahiro Takeshima, Manabu Takaki, Seiji Nishino, Tetsuo Shimiz. Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation. Neuropsychiatric disease and treatment. vol 14. 2020-10-01. PMID:29849459. |
aripiprazole (apz), a second-generation antipsychotic, is effective in treatment of depression as well as schizophrenia. |
2020-10-01 |
2023-08-13 |
human |
| Jeong Ha Park, Ji Son Hong, Sun Mi Kim, Kyung Joon Min, Un Sun Chung, Doug Hyun Ha. Effects of Amisulpride Adjunctive Therapy on Working Memory and Brain Metabolism in the Frontal Cortex of Patients with Schizophrenia: A Preliminary Positron Emission Tomography/Computerized Tomography Investigation. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 17. issue 2. 2020-10-01. PMID:30905125. |
we hypothesized that patients with schizophrenia treated with amisulpride and aripiprazole show increased working memory and glucose metabolism compared with those treated with cognitive behavioral therapy (cbt) and aripiprazole instead. |
2020-10-01 |
2023-08-13 |
Not clear |